Profile data is unavailable for this security.
About the company
Pell Bio Med Technology Co Ltd is a Taiwan-based trading company mainly engaged in the immune genetic engineering and the development of non-genetically modified cell therapy products and non-cell products. The main business focuses on immune cell therapy that uses genetic engineering to modify the patient's own immune cells. The Company is engaged in the development of chimeric antigen receptor T cell therapy for the treatment of B-cell lymphoma PL001. Non-genetically modified cell therapy products include cytokine-induced killer cells (CIK), and mixed cells using a combination of dendritic cells and cytokine-induced killer cells (DC-CIK). Non-cell products include hair care products and others.
- Revenue in TWD (TTM)17.99m
- Net income in TWD-403.74m
- Incorporated2017
- Employees--
- LocationPell Bio Med Technology Co Ltd4FNO.87, Xinhu 2nd Road, Neihu DistrictTAIPEI 114TaiwanTWN
- Phone+886 287911789
- Fax+886 287911795
- Websitehttps://www.pellbmt.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Energenesis Biomedical Co Ltd | 6.78m | -199.00m | 3.81bn | -- | -- | 5.25 | -- | 562.29 | -2.61 | -2.61 | 0.0891 | 9.53 | 0.008 | 2.69 | 7.84 | -- | -23.36 | -25.02 | -24.32 | -25.78 | 73.90 | 69.19 | -2,936.00 | -2,619.68 | 26.74 | -- | 0.0112 | -- | -2.63 | 9.01 | 1.99 | -- | -20.91 | -- |
| Unicocell Biomed Co Ltd | 19.04m | -108.55m | 4.23bn | -- | -- | 5.89 | -- | 222.36 | -1.94 | -1.94 | 0.3395 | 12.32 | 0.0247 | 1.25 | 17.87 | -- | -14.06 | -24.25 | -14.42 | -25.60 | 66.09 | 69.89 | -570.24 | -705.40 | 29.58 | -- | 0.0902 | -- | 70.79 | 34.96 | 7.73 | -- | 9.00 | -- |
| Pell Bio Med Technology Co Ltd | 17.99m | -403.74m | 5.14bn | -- | -- | 3.74 | -- | 285.73 | -8.02 | -8.02 | 0.341 | 23.77 | 0.0132 | 10.43 | 4.23 | -- | -29.90 | -- | -34.86 | -- | -113.22 | -- | -2,262.16 | -- | 7.19 | -- | 0.0985 | -- | 5.11 | -- | -73.27 | -- | -- | -- |
